Here's What Lifted Johnson & Johnson (JNJ) in Q4

Mar Vista Investment Partners, LLC, an investment management company, released its “Mar Vista U.S. Quality Strategy” fourth-quarter 2025 investor letter. A copy of the letter can be downloaded here. US equities experienced a strong momentum in 2025 and marked their second consecutive year of double-digit gains. The market witnessed one of the fastest recoveries following its dip into bear territory in April. Market leadership continued to narrow as Mega-cap stocks and AI-driven companies dominated the landscape. Against this backdrop, The Mar Vista’s U.S. Quality strategy reported +0.20% net-of-fees gains in Q4 2025 vs. the Russell 1000® Index’s +2.41% return and the S&P 500® Index’s +2.65% return. Stock selection in the communication services, consumer discretionary, and financials sectors was favorable to its performance, while stock selection in information technology, materials, and healthcare detracted from its performance. The letter also shared that, in 2026, markets will need to strike a balance between strong fundamentals and increasing economic uncertainties. In addition, please check the fund’s top five holdings to know its best picks in 2025.

In its fourth-quarter 2025 investor letter, Mar Vista U.S. Quality Strategy highlighted stocks such as Johnson & Johnson (NYSE:JNJ). Johnson & Johnson (NYSE:JNJ) was one of the strongest-performing holdings in the quarter. Johnson & Johnson (NYSE:JNJ) is a multinational company that engages in the research, development, and manufacturing of products in the healthcare field. On January 12, 2026, Johnson & Johnson (NYSE:JNJ) stock closed at $209.72 per share. One-month return of Johnson & Johnson (NYSE:JNJ) was 0.20%, and its shares gained 44.88% of their value over the last 52 weeks. Johnson & Johnson (NYSE:JNJ) has a market capitalization of $505.28 billion.

Mar Vista U.S. Quality Strategy stated the following regarding Johnson & Johnson (NYSE:JNJ) in its fourth quarter 2025 investor letter:

"Johnson & Johnson (NYSE:JNJ) stock demonstrated strong performance in Q4, driven by robust financial results, upward guidance revisions, and accelerating growth for the pharmaceutical and medical technology segments. The company's consistent execution across key business segments and positive market sentiment, despite a significant headwind from Stelera generics, contributed to its outperformance relative to broader market indices. Management continues to expect 5-7% revenue growth through 2030 which exceeds consensus estimates."

Johnson & Johnson (NYSE:JNJ) is not on our list of 30 Most Popular Stocks Among Hedge Funds. According to our database, 103 hedge fund portfolios held Johnson & Johnson (NYSE:JNJ) at the end of the third quarter, up from 95 in the previous quarter. While we acknowledge the potential of Johnson & Johnson (NYSE:JNJ) as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

In another article, we covered Johnson & Johnson (NYSE:JNJ) and shared the list of stocks Jim Cramer discussed. In addition, please check out our hedge fund investor letters Q4 2025 page for more investor letters from hedge funds and other leading investors.

READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money.

Disclosure: None. This article is originally published at Insider Monkey.